Seoul National University Bundang Hospital (SNUBH)
| 大韓民国 | トルコ | オーストリア | |
| 肺癌手術 | から $17,900 | から $17,000 | から $42,000 |
| 肺摘出術 | から $30,850 | から $10,872 | から $50,000 |
| 乳癌化学療法 | から $19,200 | から $1,200 | から $15,000 |
| 定位放射線手術 | - | から $4,500 | から $17,000 |
| 大腸癌に対する放射線療法 | - | から $7,000 | から $12,000 |
Bookimedは肺癌ステージ4治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。肺癌ステージ4治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。肺癌ステージ4治療の旅路でお一人になることはありません。
South Korea features high-authority oncology centers specializing in stage 4 lung cancer. These JCI-accredited facilities offer multidisciplinary teams, targeted therapies, and advanced diagnostics like EGFR testing. Institutions like Severance Hospital and Asan Medical Center lead in treatment for complex metastatic cases.
Bookimed Expert Insight: High-volume centers like Severance and Seoul National University Hospital treat over 10,000 patients daily. This massive volume ensures doctors maintain expertise in rare genetic mutations. Patients should prioritize clinics with integrated molecular testing centers to speed up clinical drug access.
Patient Consensus: Patients emphasize finding hospitals that perform rapid genetic testing because results dictate treatment paths. Many note that care for advanced stages shifts from surgeons to oncology teams for systemic therapy.
Korean hospitals determine Stage 4 lung cancer treatment through multidisciplinary teams and rapid molecular profiling. Specialists analyze EGFR, ALK, and ROS1 mutations alongside PD-L1 markers. This data allows doctors to prioritize targeted therapies or immunotherapy over standard chemotherapy for better patient outcomes.
Bookimed Expert Insight: Clinical volume in Seoul correlates directly with diagnostic speed and safety. Asan Medical Center manages over 2,500 inpatients daily. Seoul National University Bundang Hospital uses the digital BESTcare system to eliminate medical errors. These high-capacity systems ensure molecular results are processed faster than in smaller regional clinics.
Patient Consensus: Patients note that major centers often tailor plans based on specific organ function. Families emphasize confirming if a multidisciplinary tumor board reviewed the case before starting therapy.
Stage 4 lung cancer survival rates in South Korea range from 5.8% to 10% for 5-year relative survival. Outcomes improve significantly for patients with specific genetic mutations. Those with ALK translocations show 5-year survival rates reaching 38%. Advanced genomic testing at JCI-accredited Seoul hospitals enables these outcomes.
Bookimed Expert Insight: South Korea's high survival statistics compared to global averages stem from massive patient volumes and specialized infrastructure. Asan Medical Center alone handles over 65,000 operations annually. This concentrated expertise allows Korean surgeons to perform complex procedures like lung transplants, a milestone first achieved in Korea by Gangnam Severance Hospital.
Patient Consensus: Patients note that success often means maintaining quality of life for several years through targeted therapy. Many emphasize that fast workups and early genomic testing at Korean centers are vital for finding effective treatments.
Advanced immunotherapy and targeted drugs are available in South Korea. Clinics like Severance Hospital and Asan Medical Center offer systemic therapies including checkpoint inhibitors and molecularly targeted agents. Treatment follows precise biomarker testing for EGFR, ALK, ROS1, and PD-L1 mutations to ensure efficacy.
Bookimed Expert Insight: South Korea's oncology centers are heavily concentrated in Seoul. Large tertiary centers like Asan Medical Center serve over 11,000 outpatients daily. This massive volume allows specialists to gain experience with rare mutations. We see that patients benefit most from hospitals using advanced digital systems like SNUBH's BESTcare. These systems ensure accurate drug dosing and monitoring for complex stage 4 protocols.
Patient Consensus: Patients note that drug availability is high in major centers. They emphasize that biomarker testing speed is the real factor in starting treatment quickly.
South Korean hospitals initiate Stage 4 lung cancer treatment within 11 to 36 days. Specialized centers in Seoul often start systemic therapies within 14 days. This speed is possible due to rapid molecular testing for EGFR, ALK, and PD-L1 markers. JCI-accredited facilities maintain some of the fastest diagnostic-to-treatment timelines globally.
Bookimed Expert Insight: Patient volume is a major indicator of efficiency in Seoul. Asan Medical Center treats over 11,000 outpatients daily and manages over 65,000 yearly operations. This massive scale forces a highly streamlined workflow. This workflow ensures international patients complete staging and start treatment without traditional wait times found elsewhere. Organizations like Seoul National University Hospital, which provides care for the Korean President, set the national standard for these rapid oncology protocols.
International patients can enroll in clinical trials in Korea if they meet specific study eligibility criteria. Participation requires patients to be physically present at a JCI-accredited facility for selection. All trials must follow Ministry of Food and Drug Safety protocols and Good Clinical Practice standards.
Bookimed Expert Insight: Korea ranks high in global clinical trial capacity because major hospitals like Severance and Seoul National University Hospital operate massive outpatient centers. These facilities serve over 1,600,000 people annually. This high patient volume allows Korean centers to recruit participants faster than many Western institutions. Patients seeking targeted therapies should note that SNUH reports some of the highest cancer treatment statistics in the country.
Patient Consensus: Patients note that getting standard treatment in Korea is simpler than entering a trial. They emphasize that matching specific tumor mutations and staying near the hospital for frequent follow-up visits are the biggest practical hurdles.
Obtaining a second opinion for Stage 4 lung cancer in South Korea is standard practice and highly advisable. Specialized centers provide critical access to molecular testing for EGFR, ALK, ROS1, and PD-L1 mutations. JCI-accredited facilities in Seoul offer advanced immunotherapy and targeted options to refine treatment paths.
Bookimed Expert Insight: While patients often focus on general popularity, the raw data shows significant differences in specialized capacity. Severance Hospital maintains 3,700 beds and treats 1.6 million outpatients annually, nearly double the volume of other major centers. Choosing these high-volume facilities ensures that your second opinion comes from a team seeing thousands of similar Stage 4 cases every year.